LAUSR

Supplemental Digital Content is Available in the Text. This meta-analysis found no difference between antivascular endothelial growth factors for sight-threatening intraocular inflammation outcomes, including endophthalmitis and retinal vascular occlusions, and a higher risk of generalized intraocular inflammation and vitreous haze/floaters after brolucizumab relative to aflibercept. Purpose: This meta-analysis investigates the incidence of intraocular inflammation (IOI) after intravitreal antivascular endothelial growth factor injections in neovascular age-related macular degeneration. Methods: A systematic search was performed on Ovid MEDLINE, Embase, and Cochrane Central from January 2005 to April 2021. Randomized controlled trials comparing IOI after intravitreal bevacizumab, ranibizumab, brolucizumab, or aflibercept in neovascular age-related macular degeneration were included. Primary outcomes were sight-threatening IOI, final best-corrected visual acuity, and change in best-corrected visual acuity from baseline. Secondary outcomes included the incidence of other IOI events. Meta-analysis was performed using a random-effects model. Results: Overall, 11,460 unique studies were screened, of which 14 randomized controlled trials and 6,759 eyes at baseline were included. There was no difference between agents for the risk of endophthalmitis and retinal vascular occlusion. Compared with aflibercept, brolucizumab had a higher incidence of generalized IOI (risk ratio = 6.24, 95% confidence interval = [1.40–27.90]) and vitreous haze/floaters (risk ratio = 1.64, 95% confidence interval = [1.00–2.67]). There were no significant differences between comparators for other secondary end points. Conclusion: There was no difference in the risk of severe sight-threatening IOI outcomes between intravitreal antivascular endothelial growth factor agents. There was a significantly higher risk of generalized IOI after brolucizumab relative to aflibercept. Our results alongside other recent safety findings suggest the need for further investigation in the risk–benefit profile of brolucizumab for the treatment of neovascular age-related macular degeneration.